Business Context and Reporting Period
This Form 8-K reports on the results of the 2018 Annual Meeting of Stockholders held by Capricor Therapeutics, Inc. on June 8, 2018. The meeting took place at the company's principal executive offices in Beverly Hills, California.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 23,260,771 shares (of 28,092,138 entitled to vote) participated in the meeting. Two proposals were approved:
- Election of Directors: Seven nominees were elected to the Board of Directors to serve until the 2019 annual meeting. The nominees were Frank Litvack, M.D., Linda Marbán, Ph.D., David B. Musket, George W. Dunbar, Jr., Louis Manzo, Earl M. (Duke) Collier, Jr., and Joshua Kazam. All received significant "For" votes, with "Broker Non-Votes" totaling 8,895,013 for each nominee.
- Ratification of Auditors: The appointment of Rose, Snyder & Jacobs LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was ratified.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves solely as a disclosure of the voting outcomes.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 26, 2018, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the total number of shares outstanding and the specific breakdown of "Withheld" votes for each director nominee, particularly for Earl M. (Duke) Collier, Jr., who received the highest number of withheld votes (1,231,571).
- Review subsequent filings for the company's financial performance for the fiscal year ending December 31, 2018, as this 8-K contains no financial data.